| Date | Time | Source | Headline | Symbol | Company |
| 04/24/2024 | 4:01PM | GlobeNewswire Inc. | Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/16/2024 | 8:01PM | GlobeNewswire Inc. | Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/10/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistanc | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 04/09/2024 | 7:00AM | GlobeNewswire Inc. | Acrivon Therapeutics Announces $130 Million Private Placement Financing | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 03/28/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 03/06/2024 | 4:32PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 03/06/2024 | 4:29PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 03/05/2024 | 4:30PM | GlobeNewswire Inc. | Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 03/04/2024 | 8:15AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 03/04/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/27/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/16/2024 | 5:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/16/2024 | 5:13PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/16/2024 | 5:12PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/16/2024 | 5:10PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/16/2024 | 5:08PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/16/2024 | 5:06PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/13/2024 | 3:40PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/08/2024 | 8:27AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/08/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 02/06/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 01/19/2024 | 4:24PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 01/12/2024 | 4:00PM | GlobeNewswire Inc. | Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 01/08/2024 | 7:28AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 01/04/2024 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 12/18/2023 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 12/08/2023 | 4:21PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 12/01/2023 | 4:35PM | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 11/28/2023 | 8:58AM | Dow Jones News | Acrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer Assay | NASDAQ:ACRV | Acrivon Therapeutics Inc |
| 11/28/2023 | 8:00AM | GlobeNewswire Inc. | Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer | NASDAQ:ACRV | Acrivon Therapeutics Inc |